Patent intelligence · US
US 11512113
Cleavable linker compositions and methods
Cleavable linker compositions and methods
Patent details — US 11512113
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 29, 2022
- Expiration
- Nov 24, 2042
- Applicant
- JANUX THERAPEUTICS, INC.
- Claims
- 25
- CPC classes
- A61K, A61K47/65, A61K47/68, A61K47/6889
Quick answer
US 11512113 (Cleavable linker compositions and methods) is held by JANUX THERAPEUTICS, INC.. Status: granted. Granted Nov 29, 2022. Expires Nov 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- JANUX THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K47/65, A61K47/68, A61K47/6889, A61P, A61P35/00
More from JANUX THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11512113?
US 11512113 (Cleavable linker compositions and methods) is held by JANUX THERAPEUTICS, INC.. Status: granted. Granted Nov 29, 2022. Expires Nov 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11512113?
JANUX THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 11512113 expire?
Our index shows an expiration date of Nov 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.